HCA
EBS icon

Harbor Capital Advisors’s Emergent Biosolutions EBS Stock Holding History

Harbor Capital Advisors’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-40,859
Closed -$505K – 1302
2025
Q4 		$505K Buy
40,859
+19,684
+93% +$211K 0.04% 478
2025
Q3 		$187K Sell
21,175
-9,267
-30% -$72.1K 0.01% 608
2025
Q2 		$194K Sell
30,442
-6,462
-18% -$37K 0.01% 611
2025
Q1 		$179K Buy
+36,904
New +$305K 0.01% 621

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Harbor Capital Advisors's EBS Position: Q1 2026 in Review

Harbor Capital Advisors sold out of Emergent Biosolutions (EBS) in Q1 2026, closing a stake of 40,859 shares — an estimated $505K sold.

Harbor Capital Advisors first reported a position in EBS in Q1 2025 and held it in 4 quarters. The position peaked at $505K in Q4 2025. 190 funds tracked by Wall St. Rank hold EBS as of Q1 2026.

  • Harbor Capital Advisors reported no remaining Emergent Biosolutions position as of Q1 2026 after selling out during the quarter.
  • Harbor Capital Advisors sold 40,859 Emergent Biosolutions shares in Q1 2026, an estimated $505K.
  • Harbor Capital Advisors first reported a position in Emergent Biosolutions in Q1 2025 and held it in 4 quarters.
  • Harbor Capital Advisors's Emergent Biosolutions position peaked at $505K in Q4 2025.
  • 190 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2026.

Based on Harbor Capital Advisors's 13F filing for Q1 2026, filed 28 Apr 2026.